|
Hybridon, Inc (Amex: HBY) was a biotechnology company based in Cambridge, Massachusetts, specializing in the discovery and development of novel therapeutics and diagnostics using synthetic DNA, that merged with Idera Pharmaceuticals in 2004. == Notable investors == According to a U.S. Securities and Exchange Commission filing of May 4, 1999〔(DEFR14A for Hybridon, Inc, filed May 4, 1999 )〕 Hybridon had investors with 5% or more ownership including: * Abdullah bin Mahfouz, son of the more widely known Khalid bin Mahfouz (13/87%), along with the Bermuda-based Mahfouz proprietary Intercity Holdings (13.87%); * Yahia M. A. Laden (8.67%), half-brother of the more infamous Osama bin Laden; * Nicris Limited, directed by Yehia bin Laden, and represented by Magnin Dunand et Associées (8.59%) * Faisal Finance Switzerland, the first Islamic bank registered in Switzerland, and a fully owned subsidiary of Dar al-Maal al-Islami Trust, which was under investigation in 2007 by the U.S. Department of Justice in two separate terrorism financing probes. (6.58%). 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Hybridon」の詳細全文を読む スポンサード リンク
|